153 related articles for article (PubMed ID: 7505232)
1. Value of prostate-specific antigen as a tumor marker.
Wirth M; Manseck A; Heimbach D
Eur Urol; 1993; 24 Suppl 2():6-12. PubMed ID: 7505232
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Oesterling JE
J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
[TBL] [Abstract][Full Text] [Related]
3. [Clinical surveillance after surgery for prostate cancer].
Guercio S; Terrone C; Scarpa RM
Recenti Prog Med; 2003 Mar; 94(3):110-3. PubMed ID: 12677777
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Witherspoon LR; Lapeyrolerie T
J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
[TBL] [Abstract][Full Text] [Related]
6. Recurrent prostate cancer despite undetectable prostate specific antigen.
Takayama TK; Krieger JN; True LD; Lange PH
J Urol; 1992 Nov; 148(5):1541-2. PubMed ID: 1279216
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
8. [The role of PSA in diagnosis of prostate cancer and its recurrence].
Vergho DC; Heine K; Wolff JM
Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
10. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
Iwakiri J; Granbois K; Wehner N; Graves HC; Stamey T
J Urol; 1993 Apr; 149(4):783-6. PubMed ID: 7681118
[TBL] [Abstract][Full Text] [Related]
11. [The value of PSA density for the diagnosis of prostatic cancer and for the indication of radical prostatectomy].
Doublet JD; Ciofu C; Fouret P; Gattegno B; Thibault P
Prog Urol; 1995 Apr; 5(2):211-9, 220; discussion 219-20. PubMed ID: 7536529
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
13. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
14. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].
Wirth MP; Pilarsky C
Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844
[TBL] [Abstract][Full Text] [Related]
15. How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be?
Bock JL; Klee GG
Arch Pathol Lab Med; 2004 Mar; 128(3):341-3. PubMed ID: 14987148
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
[TBL] [Abstract][Full Text] [Related]
18. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy.
Ruckle HC; Klee GG; Oesterling JE
Mayo Clin Proc; 1994 Jan; 69(1):69-79. PubMed ID: 7505870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]